Rothwell Investment Advisors, LLC’s Charles River Laboratories CRL Stock Holding History

Rothwell Investment Advisors, LLC’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$113K	Buy	+383	New	+$101K	0.06%	265

Other funds holding CRL

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $6.36B AUM 0.55% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Van Berkom & Associates Montreal, Quebec, Canada $2.81B AUM 6.02% 1-Year Est. Return

Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Rothwell Investment Advisors, LLC's CRL Position: Q3 2026 in Review

Rothwell Investment Advisors, LLC opened a new position in Charles River Laboratories (CRL) in Q3 2026: 383 shares worth $113K. The stake represents 0.06% of the portfolio and ranks #265 among its holdings.

285 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

Rothwell Investment Advisors, LLC held 383 shares of Charles River Laboratories worth $113K as of Q3 2026.
Charles River Laboratories was a new Rothwell Investment Advisors, LLC position in Q3 2026.
Charles River Laboratories made up 0.06% of Rothwell Investment Advisors, LLC's portfolio in Q3 2026, its #265 holding.
285 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Rothwell Investment Advisors, LLC's 13F filing for Q3 2026, filed 6 Nov 2026.